Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base

Pezzi, Christopher M.; Patel-Parekh, Lina; Cole, Karin L.; Franko, Jan; Klimberg, V. Suzanne; Bland, Kirby I.

doi:10.1245/s10434-006-9124-7

Cited by 296 publications

(388 citation statements)

References 14 publications

Supporting

Mentioning

334

Contrasting

Unclassified

Order By: Relevance

“…Due to a rapidly growing and palpable large mass (≥ 5 cm) in MBC patients, MRM was the main surgical procedure in most series (Pitts et al, 1991;Gutman et al, 1995;Chao et al, 1999;Rayson et al, 1999;Al Sayed et al, 2006;Pezzi et al, 2007). However, BCS could not be precluded for appropriate MBC patients who had absolute or relative indications.…”

Section: Surgical Therapymentioning

confidence: 99%

See 1 more Smart Citation

Current Progress in the Treatment of Metaplastic Breast Carcinoma

Hu¹,

Chen²,

Zhong³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Metaplastic breast cancer (MBC) is a rare type of breast carcinoma, characterized by various combinations of mesenchymal, adenocarcinoma and other epithelial components. MBC often manifests as a large mass, with low axillary lymph node involvement and poor prognosis. Knowledge and treatment patterns about MBC demographics, presentation and tumor characteristics are very limited. In clinical practice, MBC is usually treated based on the guidelines developed for infiltrating ductal carcinoma (IDC). The ideal treatment paradigm for MBC is unknown due to its low incidence and pathological variability, so potential predictors of treatment efficacy need to be explored. This review summarizes the current models and strategies for MBC according to the published literature.

show abstract

Section: Surgical Therapymentioning

confidence: 99%

“…Metaplastic breast carcinoma (MBC) is a rare form and only occurs in between 0.02% and 5% of breast carcinoma patients (Oberman, 1987;Al Sayed et al, 2006;Pezzi et al, 2007). MBC has epithelial or mesenchymal components, and two to three different components may exist within the tumor simultaneously.…”

Section: Introductionmentioning

confidence: 99%

Current Progress in the Treatment of Metaplastic Breast Carcinoma

Hu¹,

Chen²,

Zhong³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In addition to its histopathological features, MCB also has clinical behavior distinct from those of DCB, including relatively large size at diagnosis, infrequent expression of hormone receptors, lower incidence of axillary nodal involvement than typical breast carcinoma of similar size, and high rate of extranodal metastasis (Carter et al, 2006;Pezzi et al, 2007). Although presenting more commonly as node-negative disease, the outcome in MCB is generally poor with a high risk of recurrence (Barnes et al, 2005;Carter et al, 2006;Pezzi et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

“…Although presenting more commonly as node-negative disease, the outcome in MCB is generally poor with a high risk of recurrence (Barnes et al, 2005;Carter et al, 2006;Pezzi et al, 2007). Patients with MCB usually do not benefit from conventional breast cancer chemotherapy or hormone therapy (Al Sayed et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition

Lien

Hsiao

Lin³

et al. 2007

Oncogene

184

153

View full text Add to dashboard Cite

Metaplastic carcinoma of the breast (MCB) is a poorly understood subtype of breast cancer. It is generally characterized by the coexistence of ductal carcinomatous and transdifferentiated sarcomatous components, but the underlying molecular alterations, possibly related to epithelial-mesenchymal transition (EMT), remain elusive. We performed transcriptional profiling using half-agenome oligonucleotide microarrays to elucidate genetic profiles of MCBs and their differences to those of ductal carcinoma of breasts (DCBs) using discarded specimens of four MCBs and 34 DCBs. Unsupervised clustering disclosed distinctive expression profiles between MCBs and DCBs. Supervised analysis identified gene signatures discriminating MCBs from DCBs and between MCB subclasses. Notably, many of the discriminator genes were associated with downregulation of epithelial phenotypes and with synthesis, remodeling and adhesion of extracellular matrix, with some of them have known or inferred roles related to EMT. Importantly, several of the discriminator genes were upregulated in a mutant Snail-transfected MCF7 cell known to exhibit features of EMT, thereby indicating a crucial role for EMT in the pathogenesis of MCBs. Finally, the identification of SPARC and vimentin as poor prognostic factors reinforced the role of EMT in cancer progression. These data advance our understanding of MCB and offer clues to the molecular alterations underlying EMT.

show abstract

“…No metastasis in axillary lymph nodes was found. Pure chondrosarcoma and metaplastic cancer of the breast rarely invade axillary lymph nodes and are generally hormone receptor-negative [1][2][3][4]. Microscopically, the tumor was seen with atypical chondrocytes in single lacunae which at places were binucleated and multinucleated.…”

Section: Case Summarymentioning

confidence: 99%

Primary Chondrosarcoma of Male Breast: A Rare Case

2012

View full text Add to dashboard Cite

Sarcomas of the breast are relatively rare and account for 1% of all primary malignant tumors of the breast. Pure and primary chondrosarcoma of the male breast is an extremely rare tumor. It may arise either from the breast stroma itself or from underlying bone or cartilage. Differential diagnoses include cystosarcoma phyllodes and breast metaplastic carcinoma with chondroid differentiation. Keywords Chondrosarcoma . Male breast Case SummaryAn 80-year-old man presented with a painful mass in the right breast of 9 months' duration ( Fig. 1). Physical examination revealed a firm mass occupying most of the right breast, measuring 20 cm×10 cm in size. Rate of growth was initially slow but then progressed very rapidly in past 3 months before presentation. A chest X-ray did not reveal any involvement of underlying bony cage.Fine needle aspiration smears showed clusters of atypical cells with abundant pale cell cytoplasm and moderately enlarged nuclei against the background of chondroid matrix. Total mastectomy with axillary sampling was performed, and subsequent histopathological examination confirmed the cytological diagnosis of primary chondrosarcoma with lymph nodes showing reactive hyperplasia. No metastasis in axillary lymph nodes was found. Pure chondrosarcoma and metaplastic cancer of the breast rarely invade axillary lymph nodes and are generally hormone receptor-negative [1][2][3][4]. Microscopically, the tumor was seen with atypical chondrocytes in single lacunae which at places were binucleated and multinucleated. The cells were having hyperchromatic nuclei with discrete anisokaryosis. Mitoses were rare (Fig. 2).Chondrosarcoma may occur in three different forms: as a pure chondrosarcoma, as the stromal component of a

show abstract

Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base

Cited by 296 publications

References 14 publications

Current Progress in the Treatment of Metaplastic Breast Carcinoma

Current Progress in the Treatment of Metaplastic Breast Carcinoma

Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition

Primary Chondrosarcoma of Male Breast: A Rare Case

Contact Info

Product

Resources

About